JP2023546452A5 - - Google Patents

Info

Publication number
JP2023546452A5
JP2023546452A5 JP2023524274A JP2023524274A JP2023546452A5 JP 2023546452 A5 JP2023546452 A5 JP 2023546452A5 JP 2023524274 A JP2023524274 A JP 2023524274A JP 2023524274 A JP2023524274 A JP 2023524274A JP 2023546452 A5 JP2023546452 A5 JP 2023546452A5
Authority
JP
Japan
Prior art keywords
solvate
pharmaceutically acceptable
acceptable salt
compound according
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546452A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000708 external-priority patent/WO2022084739A1/en
Publication of JP2023546452A publication Critical patent/JP2023546452A/ja
Publication of JP2023546452A5 publication Critical patent/JP2023546452A5/ja
Pending legal-status Critical Current

Links

JP2023524274A 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法 Pending JP2023546452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094808P 2020-10-21 2020-10-21
US63/094,808 2020-10-21
PCT/IB2021/000708 WO2022084739A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2023546452A JP2023546452A (ja) 2023-11-02
JP2023546452A5 true JP2023546452A5 (cg-RX-API-DMAC10.html) 2024-10-29

Family

ID=81290138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524274A Pending JP2023546452A (ja) 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法

Country Status (10)

Country Link
US (1) US20230399317A1 (cg-RX-API-DMAC10.html)
EP (1) EP4232034A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546452A (cg-RX-API-DMAC10.html)
KR (1) KR20230110516A (cg-RX-API-DMAC10.html)
CN (1) CN116635032A (cg-RX-API-DMAC10.html)
AU (1) AU2021365530A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196146A1 (cg-RX-API-DMAC10.html)
IL (1) IL302174A (cg-RX-API-DMAC10.html)
MX (1) MX2023004538A (cg-RX-API-DMAC10.html)
WO (1) WO2022084739A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP3827823A1 (en) * 2012-12-19 2021-06-02 Novartis AG Lfa-1 inhibitor formulations
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2017055924A2 (en) * 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
CA3020713A1 (en) * 2016-04-19 2017-10-26 Azura Ophthalmics Ltd. Compositions for the treatment of hyperkeratosis disorders
CA3057569A1 (en) * 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
CN110996904A (zh) * 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
US20180333357A1 (en) * 2017-05-19 2018-11-22 Ocugen, Inc. Nanoemulsions with anti-inflammatory activity
WO2019053607A1 (en) * 2017-09-18 2019-03-21 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING LIFITEGRAST
WO2019096996A1 (en) * 2017-11-17 2019-05-23 Medichem, S.A. A process to obtain a tetrahydroisoquinoline derivative
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Similar Documents

Publication Publication Date Title
JP2023546453A5 (cg-RX-API-DMAC10.html)
JP2023546915A5 (cg-RX-API-DMAC10.html)
ES2393424T3 (es) Agente farmacéutico que contiene un agonista de PPAR-delta
JP2022529315A5 (cg-RX-API-DMAC10.html)
EP3069612A2 (en) Dithiol compounds, derivatives, and uses therefor
CA2504846A1 (en) Antiviral nucleoside derivatives
KR920000788A (ko) 폴리펩티드 화합물 및 그것의 제조방법
RU2002124522A (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
US20090110734A1 (en) Quaternised ammonium cyclodextrin compounds
RU2006137706A (ru) 9-замещенное производное 8-оксоаденина
SG189161A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
EP2228064A3 (en) Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist
CN107921031A (zh) 给予谷氨酰胺酶抑制剂的方法
US20210101923A1 (en) Nucleic acid prodrugs
JP7165358B2 (ja) 角膜保護用の組成物
RU2011140701A (ru) Замещенные 3-амино-2-меркаптохинолины в качестве kcnq2/3 модуляторов
JP2022530322A5 (cg-RX-API-DMAC10.html)
DE69704833T2 (de) Derivate der thiazolidine-4-carbonsäure als cytoprotektive mittel
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
JP2008531585A5 (cg-RX-API-DMAC10.html)
HU210675B (en) Process for producing 3,3'-dithio-bis(propionic-acid) derivatives and esters thereof and pharmaceutical compositions containing the same
BRPI0210601B1 (pt) preparação para uso tópico e uso de uma preparação
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
RU2014132830A (ru) Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим vla-4
JP2017534658A5 (cg-RX-API-DMAC10.html)